home / stock / svra / svra quote
Last: | $4.915 |
---|---|
Change Percent: | 1.34% |
Open: | $4.88 |
Close: | $4.85 |
High: | $4.93 |
Low: | $4.845 |
Volume: | 283,675 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.915 | $4.88 | $4.85 | $4.93 | $4.845 | 283,675 | 03-28-2024 |
$4.85 | $4.96 | $4.85 | $4.97 | $4.83 | 356,254 | 03-27-2024 |
$4.91 | $4.87 | $4.91 | $4.93 | $4.83 | 647,226 | 03-26-2024 |
$4.82 | $4.81 | $4.82 | $4.905 | $4.76 | 447,221 | 03-25-2024 |
$4.8 | $4.91 | $4.8 | $4.91 | $4.79 | 557,186 | 03-22-2024 |
$4.89 | $4.92 | $4.89 | $4.985 | $4.88 | 365,604 | 03-21-2024 |
$4.89 | $4.86 | $4.89 | $4.92 | $4.725 | 454,158 | 03-20-2024 |
$4.86 | $4.71 | $4.86 | $4.89 | $4.63 | 520,247 | 03-19-2024 |
$4.71 | $4.71 | $4.71 | $4.74 | $4.52 | 614,915 | 03-18-2024 |
$4.71 | $4.62 | $4.71 | $4.79 | $4.6101 | 834,665 | 03-15-2024 |
$4.66 | $4.87 | $4.66 | $4.885 | $4.62 | 597,313 | 03-14-2024 |
$4.89 | $4.93 | $4.89 | $5 | $4.875 | 461,501 | 03-13-2024 |
$4.92 | $4.9 | $4.92 | $4.955 | $4.78 | 609,631 | 03-12-2024 |
$4.91 | $5.29 | $4.91 | $5.3 | $4.895 | 897,355 | 03-11-2024 |
$5.3 | $5.47 | $5.3 | $5.59 | $5.13 | 1,213,502 | 03-08-2024 |
$5.59 | $5.49 | $5.59 | $5.605 | $5.35 | 750,672 | 03-07-2024 |
$5.42 | $5.45 | $5.42 | $5.475 | $5.33 | 514,460 | 03-06-2024 |
$5.43 | $5.58 | $5.43 | $5.7 | $5.43 | 980,399 | 03-05-2024 |
$5.51 | $5.26 | $5.51 | $5.57 | $5.26 | 1,490,143 | 03-04-2024 |
$5.16 | $5.08 | $5.16 | $5.25 | $5.07 | 1,137,375 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Remains On-Track to Report Top Line Data from the Pivotal Phase 3 IMPALA-2 Trial by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP)...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024 at 5:00am PT/8:00am ET. A live web...
Savara Inc. (NASDAQ: SVRA) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 4.49% on the day to $5.35. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candid...